Logi Analytics announced that eClinical Insights has embedded its Logi Info into its core applications
Logi Analytics, an analytics company, announced that eClinical Insights, a provider of cloud-based clinical trial intelligence software, has embedded its Logi Info into its core applications, delivering comprehensive Business Intelligence (BI) capabilities, simplified reporting and visualizations for researchers. eClinical Insights offers Software-as-a-Service (SaaS) products that enable customers to take a data-driven approach to the management of clinical trials. The company's offerings include data operations management software that provides visibility into clinical trials and a clinical BI application that delivers interactive data visualizations of key performance metrics, risk indicators and data trends. eClinical Insights chose the BI tool based on its ease of use and straightforward interface.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.